Rapid Dose Therapeutics Announces Research Results Published in Frontiers in Pharmacology Journal
September 12, 2019
Burlington, ON, September 12, 2019 — Rapid Dose Therapeutics Corp. (“RDT”) (CSE: DOSE) announced today that the results of a research study conducted by the University of Nevada, Las Vegas (“UNLV”) was published in the high impact journal, Frontiers in Pharmacology, on September 10, 2019.
RDT’s proprietary QuickStrip™ technology is an oral dispersible thin film drug delivery system that rapidly delivers active medicinal agents directly to the bloodstream via transfer through the sublingual or buccal mucosa (mouth), bypassing metabolism of the active agent in the gastrointestinal tract.
A bioanalytical study was conducted in collaboration with researchers from UNLV to evaluate QuickStrip™ oral thin film delivery, in mice, of caffeine for onset time, bioavailability, and effects on the central nervous system as measured by high-performance liquid chromatography and electroencephalogram (“EEG”), compared to direct administration into the stomach via the gavage method.
The study was led by UNLV neuroscientists, Dr. Rochelle Hines and Dr. Dustin Hines, whose research programs are focused on the study of neuropsychiatric disorders including developmental epilepsies, autism, schizophrenia, depression sleep disorders, and Alzheimer’s disease.
“Our work demonstrated that by using this technology, caffeine was delivered into the bloodstream quickly and with twice the bioavailability of traditional means,” said Dustin Hines, UNLV neuroscientist and study co-author.
The study showed that QuickStrip™ delivery resulted in higher serum levels of the active agent measured between one minute and 30 minutes following administration, and greater bioavailability compared to gavage. EEG results demonstrated that QuickStrip™ delivery of caffeine is rapidly absorbed, permitting quick and effective access to the central nervous system.
“We developed QuickStrip™ as a novel and versatile delivery system with many applications, including nutraceuticals and pharmaceuticals, among others. We are excited to announce the study results from UNLV which concluded that, for caffeine, RDT’s proprietary QuickStrip™ delivery method produced greater bioavailability compared to gavage and speed of uptake comparatively,” said Mark Upsdell, CEO of RDT. “RDT will continue to expand our research programs to further strengthen our unique delivery leadership position. We are committed to providing consumers in the global medical and personal product markets research-based validation that QuickStrip™ is a delivery system that is Quick, Convenient, Precise and Discreet™,” added Upsdell.
About Rapid Dose Therapeutics
Rapid Dose Therapeutics Corp. is a publicly-traded Canadian life sciences company that provides innovative, proprietary drug delivery technologies designed to improve outcomes and quality of lives. RDT offers Quick, Convenient, Precise and Discreet™ choices to consumers. RDT is focused and committed to clinical research and product development for the healthcare manufacturing industry, including the nutraceutical and pharmaceutical industries, among others. RDT’s service-based annuity contracts drive recurring revenue which enables rapid expansion into emerging markets — generating value for consumers and shareholders. Rapid Dose Therapeutics is committed to continually create innovative solutions aimed at multiple consumer segments and future market needs — including humans, animals and plants.
For more information, visit: www.rapid-dose.com
For inquiries please contact:
Ian Fodie, CFO
Rapid Dose Therapeutics Corp.
Office (416) 477-1052
Ali Mahdavi, Managing Director
Spinnaker Capital Markets Inc.
Office (416) 962-3300
CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS: Certain information in this news release may contain forward-looking information within the meaning of applicable securities laws. Any statements that are contained in this news release that are not statements of historical fact may be deemed to be forward- looking statements. Forward looking statements are often identified by terms such as “may”, “should”, “anticipate”, “expect”, “potential”, “believe”, “intend” or the negative of these terms and similar expressions. Statements containing forward-looking information, including, without limitation, in respect of the delivery of products using the QuickStrip™ product delivery method, express, as at the date of this news release, the plans, estimates, forecasts, projections, expectations or beliefs of RDT as to future events or results and are believed to be reasonable based on information currently available to them. Forward-looking statements necessarily involve known and unknown risks, including, without limitation, risks associated with general economic conditions; adverse industry events; marketing costs; loss of markets; future legislative and regulatory developments involving cannabis; inability to access sufficient capital from internal and external sources, and/or inability to access sufficient capital on favourable terms; the cannabis industry in Canada generally, income tax and regulatory matters; the ability to implement its business strategies; competition; currency and interest rate fluctuations and other risks. Readers are cautioned that the foregoing list is not exhaustive. There can be no assurance that statements of forward-looking information, although considered reasonable by management at the time of preparation, will prove to be accurate as there can be no assurance that the plans, intentions or expectations upon which they are based will occur. Actual results and future events could differ materially from those anticipated in such statements. Readers should not place undue reliance on forward-looking information. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement.
Back to press releases page